Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook



Gene therapy halts fatal child brain disease

09 October 2017

By Charlotte Spicer

Appeared in BioNews 921

A new gene therapy has halted the progression of a fatal degenerative brain disease in a small study of affected boys.

Until now, the only effective treatment available for patients with the rare disease cerebral adrenoleukodystropy (ALD) was stem cell transplantation from a compatible donor. Yet the new therapy uses the patient's own stem cells.

'The impact of this trial has been phenomenal,' said Dr Florian Eichler at Massachusetts General Hospital in Boston, who co-led the study. 'Boys without a donor match for stem-cell transplant were often passing away within a year or two of their diagnosis. Now, with early diagnosis and gene therapy, these boys are living longer and some are thriving enough to play sports and participate in other normal day-to-day activities.'

In the global, multi-centre study, researchers collected stem cells from the blood of 17 boys aged four to 14 with the severe cerebral form of ALD, also known as 'Lorenzo's oil' disease after its depiction in a 1992 film of this name.

These patients have a faulty gene on the X chromosome which causes a build-up of fatty acids that damage the protective myelin sheath around nerves, leading to motor problems and loss of the ability to walk and talk within a few years.

The scientists used an inactive form of the HIV virus to insert a correct version of the faulty gene into the stem cells, before injecting them back into the bloodstream of the patient.

Two years after receiving the treatment, 15 of the 17 patients were functioning normally and free of major disability.

'This appears to be a terrific new therapy for many kids who had little hope before,' said Dr David Williams, president of the Dana-Farber/Boston Children's Cancer and Blood Disorders Centre in Massachusetts, and senior study author. He added that the use of a patient's own, gene-modified stem cells minimises the risk of significant side effects.

The work is ongoing with eight more boys being enrolled onto the study, and long-term follow-up of the patients.

The trial opens new avenues for using gene therapy in brain diseases. Dr Theodore Friedmann at the University of California San Diego School of Medicine, who was not involved in the study, told The New York Times: 'Many think the central nervous system is intractable and unapproachable. This study proves them wrong.'

The results of the clinical trial, published in The New England Journal of Medicine, brings this treatment closer to the clinic - with the biotechnology company bluebird bio which sponsored the study in talks with US and European regulators.

Vector blog, Boston Children's Hospital | 04 October 2017
Dana-Farber/Boston Children's | 04 October 2017
HealthDay News | 05 October 2017
The New England Journal of Medicine | 04 October 2017
New York Times | 05 October 2017


11 December 2017 - by Ewa Zotow 
Scientists revealed an innovative method which can be used to transplant blood-forming stem cells directly into the brain...
20 November 2017 - by Jennifer Willows 
A new clinical trial in California marks the first time that genome editing has been used inside the body, rather than on cells such as blood or skin which can be extracted, edited outside the body, and then replaced...

25 September 2017 - by Sarah Gregory 
A novel gene therapy can reverse the symptoms and progression of disease in a mouse model of multiple sclerosis...
12 June 2017 - by Dr Rachel Huddart 
Life-threatening allergies and asthma could one day be treated by a single injection, say researchers who have successfully treated mice using gene therapy...
25 April 2016 - by Antony Blackburn-Starza 
A UK court has struck out a claim brought against a hospital for failing to diagnose a genetic disorder when testing the claimants' second cousin three years previously...
08 November 2009 - by Dr Rebecca Robey 
Gene therapy has been used to treat two young boys with a devastating and fatal brain disease called adrenoleukodystrophy (ALD). Two years after treatment, both boys showed signs that the disease had stopped progressing and that there were no serious side effects from the gene therapy. These results, published in the journal Science, show huge promise, both for the future treatment of ALD and for the revival of investigations into the use of gene therapy to treat a wide variety ...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust


Public Conference
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation